Preclinical in vivo evaluation of sFLT secretion gene therapy for retinal and choroidal neovascularisation

sFLT 分泌基因治疗视网膜和脉络膜新生血管的临床前体内评估

• 批准号: nhmrc : 353599
• 负责人: Dr Chooi-May Lai
• 金额: $ 32.61万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-vivo-evaluation-choroidal-neovascularisation/97734
• 关键词: Preclinical; vivo; evaluation; sFLT; secretion

The aim of this project is to develop a long-term treatment for diabetes-related retinal neovascularisation, reduce the occurrence of diabetic macular oedema and provide a highly effective treatment for age-related macular degeneration related choroidal neovascularisation before vision loss. The proposed technique would potentially be a major advance in disease management by providing a significantly improved or complementary treatment to the current therapies of laser photocoagulation, vitrectomy and photodynamic therapy. The proposed strategy utilizes recombinant virus-mediated gene delivery which basically produces the therapeutic agent specifically at the location of the disease. These studies addressing the feasibility of secretion gene therapy (SGT) will be readily applicable to our Gene Discovery Program Grant (JDRF-NHMRC 219166) that is set out to identify new anti-angiogenic genes.

该项目的目的是开发糖尿病相关视网膜新生血管形成的长期治疗方法，减少糖尿病黄斑水肿的发生，并在视力丧失前为年龄相关性黄斑变性相关脉络膜新生血管形成提供高效治疗。所提出的技术可能是疾病管理的一个重大进步，通过提供一个显着改善或补充治疗的激光光凝，玻璃体切除术和光动力治疗的当前疗法。所提出的策略利用重组病毒介导的基因递送，其基本上在疾病位置特异性地产生治疗剂。这些研究解决了分泌基因治疗（SGT）的可行性，将很容易适用于我们的基因发现计划资助（JDRF-NHMRC 219166），该计划旨在确定新的抗血管生成基因。